Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi wins US approval for drug combination to treat multiple myeloma
03:40pm, Friday, 20'th Sep 2024
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treat
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
02:12pm, Friday, 20'th Sep 2024
Sanofi (NASDAQ:SNY ) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toronto
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion
Sanofi says tolebrutinib drug delayed progressive MS by 31%
05:54am, Friday, 20'th Sep 2024
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later thi
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
04:01pm, Thursday, 19'th Sep 2024
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio.
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
02:21pm, Monday, 16'th Sep 2024
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
US FDA approves manufacturing line for Sanofi's preventive RSV therapy
08:16am, Monday, 16'th Sep 2024
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's preventive respiratory syncytial virus (RSV) therapy.
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
08:00am, Monday, 16'th Sep 2024
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity and h
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
01:00am, Thursday, 12'th Sep 2024
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
01:56pm, Wednesday, 11'th Sep 2024
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
01:05am, Wednesday, 11'th Sep 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary an
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary e
While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on the r
